MX2022016437A - Composicion inyectable que comprende un analogo de gnrh. - Google Patents
Composicion inyectable que comprende un analogo de gnrh.Info
- Publication number
- MX2022016437A MX2022016437A MX2022016437A MX2022016437A MX2022016437A MX 2022016437 A MX2022016437 A MX 2022016437A MX 2022016437 A MX2022016437 A MX 2022016437A MX 2022016437 A MX2022016437 A MX 2022016437A MX 2022016437 A MX2022016437 A MX 2022016437A
- Authority
- MX
- Mexico
- Prior art keywords
- sustained
- release
- phase
- injectable composition
- gnrh derivatives
- Prior art date
Links
- 239000007972 injectable composition Substances 0.000 title abstract 3
- 101150108262 gnrh1 gene Proteins 0.000 title 1
- 238000013268 sustained release Methods 0.000 abstract 3
- 239000012730 sustained-release form Substances 0.000 abstract 3
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical class C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 239000012530 fluid Substances 0.000 abstract 2
- 239000004973 liquid crystal related substance Substances 0.000 abstract 2
- 239000012071 phase Substances 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000012141 concentrate Substances 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 239000007791 liquid phase Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- -1 sorbitan unsaturated fatty acid ester Chemical class 0.000 abstract 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Reproductive Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Dispersion Chemistry (AREA)
- Biochemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Una composición inyectable de la presente invención ha aumentado notablemente la seguridad mediante la formación, en una composición, de un éster de ácido graso insaturado de sorbitano que tiene una cabeza polar con dos o más grupos -OH (hidroxilo), que está en una fase líquida en una fase en la que no hay fluido acuoso para que se aplique fácilmente a preparaciones farmacéuticas en formas de dosificación, y que forma un cristal líquido en una fase fluida acuosa para que se presenten los efectos de la liberación prolongada de los derivados de GnRH, que se utilizan como principios farmacéuticamente activos in vivo. Además, en una composición inyectable de la presente invención, un preconcentrado de lípidos de liberación prolongada que comprende derivados de GnRH incluye agua y, por lo tanto, un agente líquido inyectable forma un gel de cristal líquido inmediatamente después de la administración, de modo que se muestran los efectos de reducir la velocidad de liberación inicial y aumentar notablemente las propiedades de liberación prolongada del fármaco.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20200080621 | 2020-06-30 | ||
| PCT/KR2021/008187 WO2022005169A1 (ko) | 2020-06-30 | 2021-06-29 | Gnrh 유도체를 포함하는 주사용 조성물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022016437A true MX2022016437A (es) | 2023-01-30 |
Family
ID=79316601
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022016437A MX2022016437A (es) | 2020-06-30 | 2021-06-29 | Composicion inyectable que comprende un analogo de gnrh. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230248801A1 (es) |
| EP (1) | EP4173614A4 (es) |
| JP (1) | JP7542661B2 (es) |
| KR (1) | KR102628523B1 (es) |
| CN (1) | CN115867258A (es) |
| AU (1) | AU2021299156C1 (es) |
| BR (1) | BR112022025817A2 (es) |
| CA (1) | CA3180468A1 (es) |
| MX (1) | MX2022016437A (es) |
| WO (1) | WO2022005169A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024003291A1 (en) * | 2022-06-30 | 2024-01-04 | Virbac | Deslorelin use in chemical castration of a non-human mammal related to pk/pd interaction |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY107937A (en) | 1990-02-13 | 1996-06-29 | Takeda Chemical Industries Ltd | Prolonged release microcapsules. |
| US5858398A (en) * | 1994-11-03 | 1999-01-12 | Isomed Inc. | Microparticular pharmaceutical compositions |
| US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
| TWI241915B (en) | 1998-05-11 | 2005-10-21 | Ciba Sc Holding Ag | A method of preparing a pharmaceutical end formulation using a nanodispersion |
| US6565874B1 (en) | 1998-10-28 | 2003-05-20 | Atrix Laboratories | Polymeric delivery formulations of leuprolide with improved efficacy |
| US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
| DK1682091T3 (en) * | 2003-11-07 | 2017-05-15 | Camurus Ab | COMPOSITIONS OF LIPIDS AND CATIONIC PEPTIDES |
| TW200529890A (en) | 2004-02-10 | 2005-09-16 | Takeda Pharmaceutical | Sustained-release preparations |
| EP1768650B1 (en) | 2004-06-04 | 2008-07-16 | Camurus Ab | Liquid depot formulations |
| EP1848403B8 (en) | 2005-01-14 | 2010-05-19 | Camurus Ab | Topical bioadhesive formulations |
| WO2012160212A1 (en) | 2011-05-25 | 2012-11-29 | Camurus Ab | Peptide controlled-release formulations |
| KR101494594B1 (ko) * | 2011-08-30 | 2015-02-23 | 주식회사 종근당 | 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물 |
| EA028040B1 (ru) * | 2011-12-05 | 2017-09-29 | Камурус Аб | Композиция-предшественник, которая образует жидкокристаллическую композицию in vivo, способ доставки биологически активного средства с ее использованием, способ ее получения и способ лечения путем ее введения |
| KR101586791B1 (ko) * | 2012-12-28 | 2016-01-19 | 주식회사 종근당 | ＧｎＲＨ 유도체의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물 |
| JP7527785B2 (ja) * | 2016-09-15 | 2024-08-05 | カムルス エービー | プロスタサイクリン類似体製剤 |
| US10994018B2 (en) * | 2017-09-27 | 2021-05-04 | Novel Pharma Inc. | Long-acting palmitic acid-conjugated GnRH derivative, and pharmaceutical composition containing same |
-
2021
- 2021-06-29 AU AU2021299156A patent/AU2021299156C1/en active Active
- 2021-06-29 MX MX2022016437A patent/MX2022016437A/es unknown
- 2021-06-29 JP JP2022581316A patent/JP7542661B2/ja active Active
- 2021-06-29 CA CA3180468A patent/CA3180468A1/en active Pending
- 2021-06-29 CN CN202180046461.0A patent/CN115867258A/zh active Pending
- 2021-06-29 EP EP21833046.2A patent/EP4173614A4/en active Pending
- 2021-06-29 WO PCT/KR2021/008187 patent/WO2022005169A1/ko active Application Filing
- 2021-06-29 US US18/010,399 patent/US20230248801A1/en active Pending
- 2021-06-29 BR BR112022025817A patent/BR112022025817A2/pt unknown
- 2021-06-29 KR KR1020210084599A patent/KR102628523B1/ko active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3180468A1 (en) | 2022-01-06 |
| JP7542661B2 (ja) | 2024-08-30 |
| US20230248801A1 (en) | 2023-08-10 |
| AU2021299156A1 (en) | 2023-01-19 |
| EP4173614A1 (en) | 2023-05-03 |
| CN115867258A (zh) | 2023-03-28 |
| AU2021299156B2 (en) | 2024-10-31 |
| AU2021299156C1 (en) | 2025-02-06 |
| WO2022005169A1 (ko) | 2022-01-06 |
| EP4173614A4 (en) | 2024-08-14 |
| BR112022025817A2 (pt) | 2023-01-10 |
| AU2021299156B9 (en) | 2024-11-07 |
| JP2023532107A (ja) | 2023-07-26 |
| KR20220002140A (ko) | 2022-01-06 |
| KR102628523B1 (ko) | 2024-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2680801C2 (ru) | Композиции и способы для лечения хронического воспаления и воспалительных заболеваний | |
| US20160136231A1 (en) | Topical formulations of chemerin c15 peptides for the treatment of dermatological conditions | |
| PH12014500449B1 (en) | Sustained-release lipid pre-concentrate of pharmacologically active substance and pharmaceutical composition comprising the same | |
| NO339802B1 (no) | Formulering for nasal anvendelse omfattende neurotransmittere | |
| PH12015500936B1 (en) | Sustained-release lipid pre-concentrate of gnrh analogues and pharmaceutical composition comprising the same | |
| US20190374508A1 (en) | Therapeutic topical compositions of apremilast | |
| JP2008540509A (ja) | 血管作用性キットおよび組成物ならびにその用途 | |
| JP2021500369A (ja) | アダパレン及びミノサイクリンの局所用医薬組成物 | |
| Mittal et al. | Status of fatty acids as skin penetration enhancers-a review | |
| MX2022016437A (es) | Composicion inyectable que comprende un analogo de gnrh. | |
| US20230149352A1 (en) | Uses of apremilast | |
| EP2116237A1 (en) | Compositions for treating rosacea comprising chitosan and a dicarboxylic acid | |
| Fortier et al. | Limitations of the ACTH regulating effect of corticoids | |
| KR101822133B1 (ko) | 헤파린의 국소 제제 | |
| JP2022531708A (ja) | 少なくともアミトリプチリンを含む水性ゲルの形態の局所用医薬組成物 | |
| KR101640944B1 (ko) | γ-오리잔올 함유 외용제 조성물 | |
| RU2560518C1 (ru) | Средство, обладающее лимфокинетической активностью | |
| JPWO2021060425A5 (es) | ||
| RU2018143557A (ru) | Карбоновые кислоты, предназначенные для применения в раннем детстве | |
| JP5999875B2 (ja) | ゲル状医薬組成物 | |
| JP2020503296A5 (es) | ||
| JP2016008184A (ja) | 皮膚外用剤とその使用方法 | |
| RU2498810C1 (ru) | Средство с 5-аминосалициловой кислотой кверцетином и экстрактом прополиса, обладающее антиоксидантной активностью | |
| EA202000097A1 (ru) | Ветеринарное лекарственное средство, обладающее утеротоническим действием, применяемое для профилактики и лечения послеродовых осложнений у животных | |
| JP2024025725A (ja) | 組成物 |